Sunifiram powder is a piperazine which has some structural similarities to piracetam. Piracetam was developed for neurodegenerative disorders like Alzheimer’s disease, and Sunifiram powder is known to enhance cognitive function in some behavioral experiments. In receptor binding studies, Sunifiram raw powder does not show affinity for most neurotransmitter receptors or channels (no affinity at 1μM for serotoninergic, dopaminergic, muscarinic, nicotinic, adrenergic, glutamatergic, histaminergic, opioid, or GABAergic receptors), yet promotes the release of acetylcholine from rat cerebral cortex, likely through positive modulation of AMPA receptor response.
ຜົງ Sunifiram ແມ່ນ piperazine ເຊິ່ງມີຄວາມຄ້າຍຄືກັນກັບໂຄງສ້າງບາງຢ່າງທີ່ເປັນ piracetam. Piracetam ໄດ້ພັດທະນາສໍາລັບຄວາມຜິດປົກກະຕິ neurodegenerative ເຊັ່ນ: ພະຍາດ Alzheimer, ແລະຝຸ່ນ Sunifiram ແມ່ນເປັນທີ່ຮູ້ຈັກເພື່ອເສີມຂະຫຍາຍການເຮັດວຽກຂອງມັນສະຫມອງໃນບາງປະສົບການການປະພຶດ. ໃນການສຶກສາທີ່ກ່ຽວຂ້ອງກັບການຜູກພັນ, ໂປຼຕີນຂອງ Sunifiram ບໍ່ໄດ້ສະແດງຄວາມສໍາພັນກັບ receptors ຫຼືຊ່ອງທາງ neurotransmitters ສ່ວນຫຼາຍ (ບໍ່ມີຄວາມສໍາພັນກັບ1μMສໍາລັບ serotoninergic, dopaminergic, muscarinic, nicotinic, adrenergic, glutamatergic, histaminergic, opioid, or GABAergic receptors) acetylcholine ຈາກ cortex cerebral ຫນູ, ອາດຈະມີການປຽບທຽບບວກຂອງການຕອບສະຫນອງຂອງ AMPA.